Ovarian cancer vaccine trial completes; new Phase 1 vaccine study registered for healthy volunteersNov 16Weekly roundup, 2 itemsMerck & Co., Inc.pembrolizumab
Amgen posts results for terminated acapatamab mCRPC trial; updates MARITIME-PEN and AMG 691 recordsNov 13Weekly roundup, 6 itemsacapatamabAMG-691Updated
Merck's KEYNOTE-057 bladder cancer trial ends with results posted; eight more registry updatesNov 13Weekly roundup, 9 itemsDaiichi SankyoMerck & Co., Inc.Updated
Lilly posts Phase 2b retatrutide renal results; registers tersolisib kidney PK studyNov 13Weekly roundup, 10 itemsabemaciclibanastrozole
Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
Exelixis registers Phase 2 trial of zanzalintinib plus pembrolizumab in squamous NSCLC maintenanceNov 12Trial updateExelixispembrolizumab
FDA adds pembrolizumab-chemo nod for biliary tract cancer; prior RCC, TMB-H actions standNov 10Regulatory decisionbelzutifanMerck & Co., Inc.Updated
FDA accelerated approval covers Padcev plus Keytruda in urothelial carcinomaNov 9Regulatory decisionenfortumab vedotinMerck & Co., Inc.
Adagene completes enrollment in Phase 2 muzastotug dose-optimization trial for MSS colorectal cancerNov 9Trial updateAdagene Inccisplatin
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Evaxion presents new EVX-01 immune data at SITC, showing ex vivo T-cell detectionNov 6Clinical readoutBioNTech SEEvaxion Biotech A/SUpdated
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
Merck collaborator posts pancreatic cancer results; new MK-1045, COPD trial records surfaceNov 6Weekly roundup, 14 itemsDaiichi SankyoensifentrineUpdated
Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Merck registers new MK-8644 psoriasis trial; RA and HIV/HPV vaccine trials continueOct 30Weekly roundup, 11 itemscabazitaxeldexamethasoneUpdated
Roche group registers Phase III UC trial, GA-AMD study; AD extension stays activeOct 30Weekly roundup, 7 itemsafimkibartastegolimab
UIC registers Phase 1 trial of Pfizer's elranatamab in plasmablastic lymphomaOct 30Weekly roundup, 11 itemsAstellas Pharmaatirmociclib
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
AbbVie posts results for Japan CLL/SLL study; also files new Phase 3 NSCLC trial vs pembrolizumabOct 23Weekly roundup, 6 itemsABBV-1480AbbVieUpdated
FDA clears efficacy supplement for Merck's Keytruda QlexOct 22Regulatory decisionMerck & Co., Inc.pembrolizumab and berahyaluronidase alfa-pmph
Takeda's dazostinag Phase 1/2 trial completes with results; ixazomib HIV study still not recruitingOct 22Weekly roundup, 2 itemsixazomibTakeda Pharmaceutical Co LtdUpdated
Merck's KEYNOTE-522 posts results in triple negative breast cancer; new PAH study starts in IndiaOct 22Weekly roundup, 5 itemsMerck & Co., Inc.pembrolizumabUpdated
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
BeOne Medicines registers Phase 1 trial of BG-T0050 in DLBCL and other B-cell cancersOct 21Weekly roundup, 5 itemsazacitidineBeiGene
Arcus Biosciences' ARC-10 lung cancer trial listed as completed as of Oct 2026 updateOct 19Trial updateArcus Biosciences, Inc.domvanalimab
Merck registers Phase 3 ovarian cancer and COPD trials; GT103/Keytruda NSCLC trial results postedOct 16Weekly roundup, 5 itemsDaiichi SankyoensifentrineUpdated
Incyte's radiolabeled INCB161734 mass balance study active, not recruitingOct 16Weekly roundup, 4 itemsINCA33890INCB161734
GSK registers large new Shingrix cardiovascular trial; DESTINY HES study update postedOct 15Weekly roundup, 4 itemsdepemokimabdostarlimab-gxly
Nurix reports Q3 2026 results as bexobrutideg enters Phase 3 and NX-2127 is droppedOct 13Quarterly updatebexobrutidegNurix Therapeutics, Inc.
Karyopharm posts results for selinexor trial testing hepatic impairment dosing, combinationsOct 9Trial updateKaryopharm Therapeutics Incselinexor
CTX-471 trial terminated after combo arm misses efficacy; two device trials await startOct 9Weekly roundup, 3 itemsCompass TherapeuticsCTX-471
Sanofi posts SAR444881 results; adds two rilzabrutinib trials and RSV AI studyOct 2Weekly roundup, 5 itemsrilzabrutinibSanofiUpdated
Merck registers two new Phase 1/2 trials; KEYVIBE-005 results remain on recordOct 2Weekly roundup, 8 itemsdolutegravir sodium and lamivudinedoravirineUpdated
BMS registers Phase 1 CAR T cell trial in kidney cancer; adds mavacamten real-world studyOct 1Weekly roundup, 5 itemsBristol Myers SquibbgolcadomideUpdated
AbbVie registers Phase 1 trial comparing upadacitinib, tofacitinib, baricitinib in healthy adultsSep 30Weekly roundup, 4 itemsABBV-722AbbVie
Exelixis registers Phase 2 trial pairing zanzalintinib with pembrolizumab in NSCLCSep 29Trial updateExelixispembrolizumab
Merck posts two Phase 3 trials, sotatercept in HFpEF and sac-TMT in bladder cancerSep 24Weekly roundup, 4 itemsMerck & Co., Inc.sotatercept-csrk
PDS Biotech publishes VERSATILE-002 Phase 2 results for PDS0101 in JAMA OncologySep 22Clinical readoutPDS Biotechnology Corp
Summit reports updated HARMONi overall survival data at WCLC 2026Sep 15Clinical readoutivonescimabSummit Therapeutics
Summit Therapeutics registers Phase 2/3 HARMONi-GU1 trial in urothelial carcinomaSep 11Trial updateivonescimabSummit Therapeutics
Pyxis Oncology reports updated Phase 1 data for MICVO in head and neck cancerSep 9Clinical readoutPyxis Oncology, Inc
Bayer registers India observational study of darolutamide in mHSPCSep 9Weekly roundup, 2 itemsBayerdarolutamide
Inhibrx reports Phase 2 HNSCC data showing INBRX-106 combo nearly doubles response rateSep 8Clinical readoutInhibrx Biosciences, Inc
Bicara Therapeutics updates registry record NCT07807163: recruitingSep 8Trial updateBicara Therapeuticsficerafusp alfaRecord notice
Sutro Biopharma registers Phase 1 first-in-human trial of ADC STRO-006 in solid tumorsSep 8Trial updateSTRO-006Sutro Biopharma, Inc.
JAVELIN Bladder Medley results posted; Merck files separate MK-2010 trial across six tumor typesSep 1Weekly roundup, 2 itemsavelumabbelzutifan
Novartis-linked melanoma trial posts results; new ITP preference survey and LASIK study activeAug 27Weekly roundup, 4 itemsdabrafenibitraconazole
Revolution Medicines registers Phase 3 zoldonrasib trial for RAS G12D-mutated NSCLCAug 20Trial updateRevolution Medicines, Inc.zoldonrasib
Lilly registers Phase 3 depression trial; posts results for two psoriasis and oncology studiesAug 20Weekly roundup, 5 itemsabemaciclibbrenipatide
AstraZeneca halts eVOLVE-Lung02 trial of volrustomig in lung cancerAug 17Clinical readoutAstraZenecavolrustomig
Citius Pharmaceuticals reports fiscal Q3 2026 results as LYMPHIR launch continuesAug 14Quarterly updateCitius Pharmaceuticals, Inc.denileukin diftitox-cxdl
BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 resultsAug 14Quarterly updateBeyondSpring Pharmaceuticals Inc.
TuHURA reports Q2 2026 results, outlines second-half milestones for AML and MCC programsAug 14Quarterly updateKintara Therapeutics, Inc.
Citius Oncology reports LYMPHIR order growth in fiscal Q3 2026, expands sales forceAug 14Quarterly updateCitius Oncology, Inc.Citius Pharmaceuticals, Inc.
Pyxis Oncology reaffirms MICVO data timelines, closes $50 million private placementAug 13Quarterly updatePyxis Oncology, Inc
AbbVie posts Crohn's OLE results; registers Phase 3 lung cancer and Phase 1 glabellar lines trialsAug 13Weekly roundup, 3 itemsABBV-1480AbbVie
Candel targets Q4 2026 BLA for prostate cancer therapy, opens NSCLC phase 3 trialAug 13Quarterly updateCandel Therapeutics, Inc.
NextCure's NC410-pembrolizumab trial ends after Phase 1b; Part 2 never launchedAug 13Trial updateMerck & Co., Inc.NC410
Eikon Therapeutics reports Q2 2026 results with seven ESMO abstracts and melanoma trial progressAug 13Quarterly updateEikon Therapeutics
Inhibrx reports Q2 2026 results, sets Q3 PFS readout for INBRX-106Aug 13Quarterly updateInhibrx Biosciences, Inc
Adagene reports mid-2026 results, muzastotug data across CRC and HCC trialsAug 12Quarterly updateAdagene Inc
Bicara names successor CEO, reports pivotal trial on track for 2027 readoutAug 11Quarterly updateBicara Therapeutics
Genmab terminates Phase 1/2 GEN1055 trial for strategic reasons; results now postedAug 11Trial updateBioNTech SEGEN1055
BridgeBio Oncology reports Q2 2026 results, starts two KRAS inhibitor combination trialsAug 11Quarterly updateBridgeBio Oncology Therapeutics, Inc.
Pliant reports Q2 2026 results, adds two oncology-focused directors as FORTIFY enrollment continuesAug 11Quarterly updatePliant Therapeutics, Inc.PLN-101095
AbbVie registers three new trials spanning obesity, head and neck cancer, and atopic dermatitisAug 7Weekly roundup, 3 itemsABBV-295AbbVie
Actuate-linked trial of 9-ING-41 plus carboplatin in salivary gland cancer posts resultsAug 7Trial updateActuate Therapeutics Inc.pemetrexed
Iovance posts record Q2 2026 revenue, gains FDA fast track for lifileucel in sarcomasAug 6Quarterly updateIovance Biotherapeutics, Inc.lifileucel
Generate Biomedicines reports Q2 2026 results, advances asthma and oncology pipelineAug 6Quarterly updateGenerate Biomedicines
Foghorn reports Q2 2026 results, FHD-909 trial on track with LillyAug 6Quarterly updateEli LillyFoghorn Therapeutics Inc.
Immunocore posts Q2 KIMMTRAK sales growth as key melanoma trial nears enrollment targetAug 6Quarterly updateImmunocore Ltdtebentafusp
Exelixis registers Phase 3 STELLAR-316 trial of zanzalintinib in colorectal cancer MRDAug 6Trial updateExelixisMerck & Co., Inc.
Corbus reports Q2 2026 results, clears FDA hurdle for CRB-701 trialAug 6Quarterly updateCorbus Pharmaceuticals Holdings, Inc.
Arvinas registers first-in-human Phase 1/2 trial of ARV-6723 in advanced solid tumorsAug 6Trial updateARV-6723Arvinas Inc.
CytomX reports Q2 2026 results, advances Varseta-M toward first registrational studyAug 6Quarterly updateCytomX Therapeutics
Summit Therapeutics starts Phase II/III bladder cancer trial for ivonescimabAug 5Clinical readoutivonescimabSummit Therapeutics
Revolution Medicines advances daraxonrasib NDA and reports new lung cancer combination dataAug 5Quarterly updatedaraxonrasibRevolution Medicines, Inc.
Merck posts Q2 loss on Terns charge, raises full-year sales outlookAug 4Quarterly updateMerck & Co., Inc.
Precigen posts first quarterly profit as PAPZIMEOS revenue more than doublesAug 4Quarterly updatePrecigen, Inc
Gilead reports Q2 2026 results with three FDA approvals, three positive Phase 3 readoutsAug 4Quarterly updateGilead Sciences
Krystal Biotech posts second-quarter results, outlines multiple late-2026 pipeline readoutsAug 3Quarterly updateKrystal Biotech, Inc.
Iovance's cervical cancer TIL trial C-145-04 terminated after meeting event thresholdJul 31Trial updateIovance Biotherapeutics, Inc.lifileucel
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
GeoVax reaffirms Q4 start for GEO-MVA pivotal trial, reports $3.1 million cashJul 27Quarterly updateGeoVax Labs, Inc.
NuCana's NuTide:303 trial for NUC-3373 combos terminated; results posted with 19 enrolledJul 23Trial updatefosifloxuridine nafalbenamideNuCana plc
Anixa Biosciences-linked TNBC vaccine trial posts completed results after five-year runJul 17Trial updateAnixa Biosciences Inc
Immutep reports 30.9-month median survival in Phase I NSCLC combination trialJul 13Clinical readoutIMMUTEP Ltd
GSK posts bepirovirsen QT results; registers Mo-Rez ovarian, endometrial Phase 3 trialsJul 10Weekly roundup, 6 itemsbepirovirsencamlipixant
Pyxis Oncology announces up to $114 million private placement for MICVO programJul 2FinancingPyxis Oncology, Inc
Genmab-BioNTech trial of GEN1042 combos posts results after early end for lack of efficacyJul 2Trial updateBioNTech SEGEN1042